What is Leerink Partnrs’ Estimate for AXSM FY2028 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at Leerink Partnrs reduced their FY2028 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Friday, February 21st. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $9.30 per share for the year, down from their previous forecast of $9.70. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.74) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2029 earnings at $16.05 EPS.

A number of other research analysts have also issued reports on AXSM. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 target price on the stock. HC Wainwright upped their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday. Robert W. Baird set a $132.00 target price on shares of Axsome Therapeutics in a report on Monday, February 3rd. Truist Financial upped their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.79.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $137.75 on Monday. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05. The company has a current ratio of 2.11, a quick ratio of 2.37 and a debt-to-equity ratio of 3.22. The company’s 50-day moving average is $101.29 and its two-hundred day moving average is $94.99. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Institutional Trading of Axsome Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AXSM. Boxer Capital Management LLC acquired a new stake in Axsome Therapeutics during the 4th quarter worth approximately $39,767,000. Lazard Asset Management LLC grew its position in Axsome Therapeutics by 525.7% in the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company’s stock valued at $45,492,000 after acquiring an additional 451,737 shares in the last quarter. Norges Bank acquired a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $34,100,000. BVF Inc. IL grew its position in Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock valued at $117,444,000 after acquiring an additional 342,064 shares in the last quarter. Finally, Iron Triangle Partners LP acquired a new stake in Axsome Therapeutics in the third quarter valued at approximately $22,671,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.